REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...

Recursion Pharmaceuticals (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing ...

It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals (NASDAQ: RXRX). Earlier this year, the company's shares skyrocketed after it announced a partnership with the ...